Clarence Findley, MD
Interventional Cardiology · Fredericksburg, VANPI 1962644310
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.2%), food and beverage and grants — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Abbott at 27.6% of the total.
Across 283 payments — averaging $67.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$5K
- Boston Scientific$3K
- Edwards Lifesciences$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$675
- Novartis$417
- plus $3K from 33 others
What the payments were for
- Grants$2,50013%
- Travel & lodging$8,78746%
- Food & beverage$7,74941%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 25 | $5,260 |
| Medtronic(2 entities) | 30 | $4,549 |
| Boston Scientific | 39 | $3,252 |
| Edwards Lifesciences | 20 | $1,850 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $675 |
| Novartis | 28 | $417 |
| Biotronik Inc. | 5 | $263 |
| Abiomed | 4 | $257 |
| Amgen | 15 | $246 |
| Pfizer | 10 | $188 |
| Inari Medical, Inc. | 1 | $174 |
| Novo Nordisk | 7 | $163 |
| Philips North America LLC | 8 | $160 |
| E.r. Squibb & Sons, L.L.C. | 8 | $142 |
| Shockwave Medical, Inc | 1 | $137 |
| Irhythm Technologies, Inc. | 2 | $136 |
| Scpharmaceuticals Inc. | 5 | $135 |
| Baxter Healthcare | 2 | $98 |
| AstraZeneca | 4 | $90 |
| Boehringer Ingelheim | 5 | $73 |
| Alnylam Pharmaceuticals Inc. | 4 | $70 |
| Atricure, Inc. | 2 | $63 |
| Heartflow, Inc. | 3 | $61 |
| Cardiva Medical, Inc. | 2 | $59 |
| Cvrx, Inc. | 3 | $58 |
| Biosense Webster, Inc. | 2 | $55 |
| Johnson & Johnson | 3 | $55 |
| Terumo Medical Corporation | 1 | $53 |
| Bayer | 2 | $50 |
| Medicomp Inc | 1 | $36 |
| Cleerly, Inc. | 1 | $35 |
| Merck | 2 | $33 |
| Recor Medical Inc | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| G Medical Diagnostic Services, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$2,988
- VersaCross Access Solution$2,112
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,178
- TRICLIP$1,106
- AMPLATZER AMULET$903
- COREVALVE EVOLUT R$442
- CoreValve Evolut$243
- COROFLOW$207
- FLOWTRIEVER CATHETER, S$174
- CT THROMBECTOMY SYSTEM KIT$174
- 3F$167
- AMPLATZER$152
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$137
- OPTICROSS$135
- SAPIEN 3 Ultra RESILIA$120
- ZIO XT Patch$117
- Zio monitor$117
- ONYX FRONTIER$110
How this compares
$19,036 in reported general payments places this provider in the 80th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 59 | $53,436 |
| EntrestoSacubitril/Valsartan | 32 | $32,192 |
| Repatha SureclickEvolocumab | 19 | $17,005 |
| Repatha SyringeEvolocumab | 11 | $6,067 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 45 | $4,091 |
| Nifedipine ErNifedipine | 55 | $1,610 |
| Rosuvastatin Calcium | 112 | $1,432 |
| Metoprolol Succinate | 114 | $1,201 |
| Nebivolol Hcl | 11 | $838 |
| Candesartan Cilexetil | 24 | $819 |
| Carvedilol | 94 | $586 |
| Atorvastatin Calcium | 47 | $518 |
| ClopidogrelClopidogrel Bisulfate | 51 | $498 |
| Olmesartan Medoxomil | 32 | $443 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 63 | $396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $188 | $53,43659 claims |
| NovartisEntresto | $417 | $32,19232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Fredericksburg
- Rajiv TayalFredericksburg$984K
- Thomas MartyakFredericksburg$66K
- Zeshan RanaFredericksburg$23K
- Arijit ChandaFredericksburg$11K
- Deepak TalrejaVirginia Beach$1.5M
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Noah JonesFalls Church$238K
- Michael GenVirginia Beach$207K
- Jeremy BockLeesburg$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.